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Summary Recent arouse of interest indicated that drug resistant proteins are
markedly over-expressed in the epileptogenic tissue and they may be responsible
for the one-third of the epileptic patients who were refractory to anti-epileptic drugs
(AEDs). Since several AEDs may act as substrates for these drug resistant proteins, the
enhanced function of such proteins may increase drug extrusion, resulting in inade-
quate response to drug therapy in patients with epilepsy.
We studied expression of the multidrug resistance protein 1 (MDR1) and multidrug
resistance-associated protein 1 (MRP1) in the epileptic tissues resected surgically in
28 patients with focal cortical dysplasia (FCD) by immunohistochemistry. The results
were compared with 10 normal necropsy brain tissues.
Normal brain showed no MDR1 expression in neurons and astrocytes, while MRP1
expression was very weak, which were encountered in a few samples. MDR1 expres-
sion was mainly localized on the vascular endothelial cells. In contrast to normal
brain, we found intense MDR1 and MRP1 expression in both neurons and reactive
astrocytes in the vast majority of dysplastic tissues. The majority of the dysplastic
neurons demonstrated moderate to strong MRP1 immunoreactivity. Endothelial cells
showed both MDR1 and MRP1 expression in the majority of the specimens studied.
Multidrug transporters are over-expressed in the epileptogenic zone in patients
with FCD. These results are concordant with previous studies, in which over-expres-
sion of multidrug proteins were shown in epileptogenic brain tissue in patients with* Corresponding author at: P.K: 5, 34301 Cerrahpasa, Istanbul, Turkey. Tel.: +90 212 414 34 27; fax: +90 212 414 34 27.
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FCD, that the over-expression of drug transport proteins in tissue from patients with
refractory epilepsy may explain one possible mechanism for drug resistant in these
pathologies.
# 2007 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
Failure to respond to the therapeutic concentra-
tions of antiepileptic drugs (AEDs) is the usual basis
for defining multiple drug resistance epilepsy, but
the main mechanism(s) underlying the drug resis-
tance to AEDs is still largely unknown. It seems
likely that one possible explanation that has
emerged as a credible potential factor recently
is impairment of drug penetration into the brain by
efflux transporters. It has been hypothesized that
over-expression of efflux transporters, such as ATP-
binding cassette proteins (ABC), at the blood-
brain-barrier (BBB), which prevents AEDs from
reaching sufficiently high brain concentrations
despite adequate plasma levels, could be one such
mechanism.1 In recent years, much attention has
been focused on the mediators of multidrug resis-
tant proteins (MDRPs) in a variety of clinical enti-
ties including some forms of cancer2 and medically
refractory epilepsy syndromes such as temporal
lobe epilepsy due to hippocampal sclerosis (HS),3
malformations of cortical development,4 tuberous
sclerosis (TS)5 and dysembryoplastic neuroepithe-
lial tumors (DNETs).6,7
Amongst the best-understood mediators of drug
resistance are multidrug resistance gene-1 p-glyco-
protein (MDR1) and multidrug resistance-associated
protein-1 (MRP1), both of which are the members of
the ABC transporter superfamily.1,8—10 It has been
demonstrated that the brain under normal circum-
stances is protected by MDR1 and MRP1, which
contribute to the BBB and blood-cerebrospinal fluid
(blood-CSF) barrier, respectively. Such barrier trans-
porters can specifically and efficiently remove a
drug from the central nervous system, thereby limit-
ing the accumulation of such drug in the brain. MDR1
is most probably found on the vessel endothelium,
whilst MRP1 is found only in the choroid plexus
epithelium in normal brain.11
Despite advances in AED theraphy, about one-
third of patients with epilepsy are resistant to drug
treatment. The consequences of uncontrolled
epilepsy can be severe and include shortened life
span, neuropsychological impairment and social dis-
ability. Focal cortical dysplasia is (FCD) not only
a congenital maldevelopment of the cortical
tissue but also one of the most common maldeve-
lopment causing refractory epilepsy. Resistant tothe pharmacological treatment with broad range
of AEDs is also one common characteristic feature
of FCD.
Several studies demonstrating the over-expres-
sion of MDRPs in brain tissues of patients with
temporal lobe epilepsy with or without HS have
been reported, however; the neuronal expression
of MDRPs was observed in only a limited number of
patients with FCD.6,7,12,13 Therefore, this led us to
investigate the best-understood mediators, MDR1
and MPR1, of drug resistance in epileptogenic tissue
of the patients with FCD in a prospective study
including higher number of patients than the pre-
viously reported studies. In addition, we have eval-
uated relationship between MDRPs and duration of
epilepsy, number of AEDs, seizure frequency before
and after AEDs.Material and methods
Patients and controls
This study was performed with the collaborative
effort of Neurosurgery, Neurology and Pathology
departments of Istanbul University, Cerrahpasa
Medical Faculty. The formalin-fixed paraffin-
embedded 28 human brain tissues from pathological
archives were studied for detection of MDR1 and
MPR1 by immunohistochemistry method. The Local
Joint Ethics Committee of Istanbul University
approved the study. The classification system pro-
posed and modified by Mischel et al.14 and Palmini
et al.,15 respectively, was used for grading FCD. All
patients had medically intractable epilepsy prior to
surgery and had been exposed to multiple (at least
two) AED and they underwent interictal-ictal video-
EEG monitarization (with intracranial recordings
when necessary), high resolution MRI, neuropsycho-
logical and psychiatric examination for presurgical
evalution. Mean age at seizure onset was 6.27  7.2
and mean duration of epilepsy was 14.57  12.8
years. Table 1 summarizes the demographic data
of the patients included in this study.
All patients were underwent either tailored
surgical resection of the epileptogenic cortical
tissues according to the intracranial recordings
or lesionectomy. Complete removal was accom-
plished in 23 patients (82.14%) and extends of
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Table 1 Summary of demographic and histopathological data of the patients with FCD
Case Age
(y)/sex
Seizure
onset (y)
Duration of
epilepsy (y)
AEDs used
(number)
Location Histopathology
(FCD)
Engel
class
1 14/F 5 9 2 R-O IA IA
2 17/F 7 10 4 L-F IA IA
3 1/M 0.1 1 2 R-F IB III
4 37/M 20 17 2 R-T IB IA
5 8/F 2.5 5.5 3 R-F IB IA
6 10/M 1.5 8.5 4 R-T IB III
7 22/F 2 20 2 R-T IIA IA
8 16/M 10 6 2 R-F IIA IA
9 31/M 5 26 3 R-F IIA III
10 16/F 0.5 15.5 2 R-F IIA IA
11 51/F 20 31 3 L-F IIA IA
12 17/M 6 11 2 R-T IIA IIA
13 19/M 6 13 2 R-T IIA IA
14 6/M 1 5 3 L-F IIA IV
15 35/M 0.7 34 2 L-F IIB IA
16 3/M 1 2 2 L-F IIB IA
17 7/M 1 6 3 R-F IIB III
18 22/M 21 1 2 R-T IIB IA
19 6/F 2 4 3 R-F IIB IA
20 29/M 20 9 3 R-F IIB IA
21 8/F 0.7 7 2 L-T IIA IA
22 18/M 9 9 3 R-T IA IIA
23 27/F 20 7 3 R-T IIA IIA
24 50/F 0.5 49.5 2 L-TP IIA IA
25 12/M 0.6 11 2 R-F IB IIA
26 40/M 7 33 2 R-T IIA III
27 38/M 1 37 2 L-T IIA IA
28 24/M 0.5 23.5 2 L-T IA IA
AEDs: anti-epileptic drugs; F: frontal lobe; FCD: focal cortical dysplasia; L: left; O: occipital lobe; TP: temporoparietal lobe.resection was detected by postoperative brain MRI
scans. Large dysplastic neurons, disordered lami-
nar architecture, variable size and numbers of
balloon cell often located in the deeper regions
of the cortex and the underlying white matter were
the main characteristic histopathological findings
found in all patients. Postoperative seizure out-
come was classified according to Engel.16 The con-
trol group included 10 age-matched autopsy
specimens of human brain with no history of sei-
zures. The control specimens were obtained within
24 h following death.
Tissue preparation
All tissues studied were fixed in 10% buffered
formalin and formalin-fixed, paraffin-embedded tis-
sue was sectioned at 5 mm and mounted on
organosilane-coated slides (Sigma, St. Louis, MO,
USA). Neuropathological revision of the cases was
performed on hematoxylin and eosin (H-E)
stained sections together with Luxol fast blue
and Bielschowski stained permanent sides.Neuroflament (Neu), vimentin, glial fibrillary acidic
protein (GFAP), and microtubule-associated protein
(MAP2) primary antibodies were used immunohisto-
chemically for diagnosis of the different cell types.
Histopathological evaluation was done according to
Palmini et al.15 The presence of cortical laminar
disruption and cytological abnormalities were con-
sidered.
Group of neuronal cells which had small diameter
with large nucleus and narrow cytoplasm, were
found in the cortex, they were identified as imma-
ture neurons. Dysmorphic neurons were recognized
as disoriented cells with abnormal shape, atypical
dendritic process with clump of Nissl substance.
They showed strong cytoplasmic Neu positivity.
Giant neurons were bigger size neurons comparing
with V layer pyramidal neurons, which had central
nucleolus and showed moderate cytoplasmic Neu
positivity. Ballon cells were observed if they existed
in the cortex or subcortical white matter, as the
cells that had eccentric nucleolus with ballooned
opalescent eosinophilic cytoplasm without any Nissl
substance. Some of them showed GFAP (or MAP2)
496 H. Ak et al.but the others showed Neu immunopositivity. They
were all vimentin positive.
Antibodies
For detection of MDR1 expression, monoclonal anti-
bodies C18-0160 (1:250 dilution; Zymed Laboratories
Inc., San Francisco, CA, USA) were used. They recog-Table 2 Multidrug resistance protein immunocytochemica
Neurons Astrocytes Endothelial cells
MDR1 MRP1 MDR1 MRP1 MDR1 MRP1
Cases
1    +  
2    + + 
3 +    + 
4 ++ +  +  
5  ++   + 
6      
7    +  
8  +  + ++ +
9  ++  +  
10  +  +  
11  ++  ++  +
12 +  + ++ + +
13  +  +  
14  +    
15   +  + 
16      
17  +    
18 + +   + +
19 +    + 
20      ++
21 ++     
22 ++ +   + +
23 + + ++ + ++ +
24 ++ + + + + 
25 ++ ++ + +  
26 ++ + ++ + ++ 
27 ++ + ++ +  
28 ++ + ++ ++  
Controls
1     + 
2     + 
3      
4    +  
5      
6      +
7      
8     + 
9     + 
10     + 
MDR1: multidrug resistance protein 1; MRP1: multidrug resistance-
moderate staining; (++): strong staining.
Control group showed no staining for MDR1 in both neurons and astroc
patients (28.6%)] staining for MDR1 in neurons andmoderate [four pat
in astrocytes was seen in patients. No moderate or strong staining for
patients (50%) showed moderate to strong staining for MDR1 and Mnize the different internal epitopes of the MDR1
molecule. To detect MRP1 expression, monoclonal
antibodies C18-7246 (1:100 dilution; Zymed Labora-
tories Inc., San Francisco, CA, USA) were used. These
antibodies havebeenwell-characterized, recognized
separate internal epitopes of the MRP1 molecule.
Furthermore, these are believed to be specific for
MRP1, with no cross-reactivity.l distribution in different cells
Giant neurons Dysmorphic neurons Balloon cells
MDR1 MRP1 MDR1 MRP1 MDR1 MRP1
 
 
 ++
 +
   
 +  +
   
   +
   ++
  ++ +
   +
   +
++    ++ 
   +  
 +  +  +
   +  
 + ++   +
     
++ 
 +
++ ++
++ +
++ ++
 
associated protein 1; (): no staining; (): weak staining; (+):
ytes. However; moderate [five patients (17.9%)] to strong [eight
ients (14.3%)] to strong [four patients (14.3%)] staining for MDR1
MRP1 in neurons of controls was seen whereas 13 (46.4%) and 14
RP1, respectively.
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Labeled tissue sections were dried at 37 8C over-
night, and then dewaxed in xylene for 15 min prior
to rehydration in graded alcohols. Endogenous per-
oxidase activity was inhibited by incubation in 6%
H2O2 in methanol for 30 min, followed by washing in
tap water. Antigen retrieval was performed by boil-
ing sections in 0.01 M citrate buffer (pH 6.0) for
5 min. After incubation overnight at 4 8C in the
diluted primary antibody, sections were washedFigures 1—3 (1) Neurons in dysplastic tissue showed immu
proportion of cases. On the other hand, no staining with MDR1
control tissues. (2) Immunopositivity with both MDR1 (a) and
staining in neurons of control tissue.twice for 15 min in tris-buffered saline (TBS). Bound
antibodies were detected using biotinylated anti-
species-specific immunoglobulins. Then sections
were washed twice in TBS for 15 min, and then
developed using avidin-peroxidase (1:400 dilution
in 0.125 M TBS). The immunoreaction was devel-
oped with 0.05% 3,3-diaminobenzidine activated
with 0.01% H2O2. After washing in running tap water
for 5 min, sections were counterstained with hema-
toxylin and eosin. In order to differentiate the
neuronal tissue from the glial one, an antibodynopositivity with MDR1 (a) and particularly MRP1 (b) in a
and weak staining in some cases were demonstrated in 10
MRP1 (b) in giant neurons of dysplastic tissue. (3) MRP1
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Figures 4—7 (4) In eight patients, moderate to strong staining with MDR1 (a) in astrocytes was present whereas the vast
majority of astrocytes showed immunopositivity with MRP1 (b) whilst No MDR1 staining was seen in 10 controls and only
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USA), which detects specifically the neuron specific
antigen, neurofilament, was used. Four-point scale
for evaluating the immunoreactivity (IR) of MDR1
and MRP1 was used: , no staining; , weak stain-
ing; +, moderate staining and ++, strong staining.
Statistical analysis
All values were expressed as mean  S.D. and ‘‘p’’
value was considered statistically significant if less
than 0.05. The comparison between the patients
and controls related to MDRPs in neurons, astro-
cytes, and an endothelial cell was analyzed by
Mann—Whitney U-test. Paired Student’s t-test was
used for the comparison between seizure frequency
before and after AEDs. For correlation analysis
between MDRPs and number of AEDs used, duration
of epilepsy, seizure frequency before and after
AEDs, the Pearson correlation coefficient was
calculated.Results
When we compared the patients and controls
regarding to MDR1 and MRP1 in neurons and astro-
cytes, statistically significant difference was found
both in neurons ( p = 0.007 and 0.004 for MDR1 and
MRP1, respectively) and in astrocytes ( p = 0.04 and
0.01 for MDR1 and MRP1, respectively). However,
endothelial cells did not show statistically signifi-
cant difference ( p = 0.34 and 0.06 for MDR1 and
MRP1, respectively). Paired Student’s t-test demon-
strated no significant difference between the sei-
zure frequencies before and after AEDs used
( p = 0.18). Table 2 demonstrates the results of both
MDR1 and MRP1 IR in patients with FCD included in
this study.
MDR1 and MRP1 expression in neurons,
giant neurons, and dysmorphic neurons
Both MDR1 and MRP1 IR were encountered in the
neuronal component of the majority of FCD (Fig. 1a
and b). In 14 patients (50%) with MDR1 positive
specimens, moderate (five patients, 35.7%) to
strong (eight patients, 64.2%) staining was
observed in the majority of the patients. In 22
patients (78.5%) with MRP1 positive staining, simi-two of 10 controls were stained with MRP1 (one moderate and
(a) and MRP1 (b) immunoreactivity in endothelial cells. In con
MDR1 staining, mostly weak, was found in nine, consisting wit
cells in control tissue. (7) Of the six focal cortical dysplasia with
(b) staining.larly, moderate IR was seen in 13 patients (59%). Of
the 28, 12 patients (42.8%) demonstrated both
MDR1 and MPR1 IR and these were also moderate
to strong staining.
We demonstrated giant neurons in 19 patients
(67.8%) and the vast majority of the patients showed
no staining either with MDR1 or MRP1. Of 19 patients
with giant neurons, three stained moderately with
MDR1 but, six stainedmoderately with MRP1, mainly
moderate (Fig. 2a and b).
When considering dysmorphic neurons, 19
patients (67.8%) were included in this group and
moderate to strong MRP1 IR was noted in 14 (73.6%)
patients.
No significant correlation between number of
AEDs, duration of epilepsy, seizure frequency
(before/after AEDs used) and MDR1/MRP1 expres-
sion in neurons, giant neurons, and dysmorphic
neurons was obtained ( p > 0.05), arguing against
the possibility that MDRP expression was related to
seizure frequency and epilepsy duration as well.
In agreement with previous reports, antibodies
directed against MDR1 demonstrated no neuronal
labeling and only five showed weak MRP1 IR in
control normal cortex (Fig. 3).
MDR1 and MRP1 expression in reactive
astrocytes
Nine patients (32.1%) showed IR for MDR1 that often
stained strongly (Fig. 4a). Prominent staining of cell
with reactive astrocytic morphology was demon-
strated with MRP1 (Fig. 4b). In 16 patients
(57.1%), reactive astrocytes revealed moderate to
strong MRP1 IR.
In control group, there was no MDR1 IR in astro-
cytes and weak IR to MRP1 was shown in five speci-
mens.
No significant correlation between number of
AEDs, duration of epilepsy, seizure frequency
(before/after AEDs used) and MDR1/MRP1 expres-
sion in reactive astrocytes was demonstrated
(p > 0.05).
MDR1 and MRP1 expression on endothelial
cells
In 15 (53.5%) and 13 (46.4%) patients, we demon-
strated MDR1 and MRP1 IR in vessels within the
epileptogenic zone, respectively (Fig. 5a and b).one weak). (5) Majority of patients also showed both MDR1
trols, only one case showed moderate MRP1 staining and
h the literature. (6) MDR1 immunopositivity in endothelial
balloon cells, two showedMDR1 (a) and two showed MRP1
500 H. Ak et al.The vast majority of 15 patients showed prominent
staining, ranging mainly from moderate to strong,
with MDR1. In agreement with previous reports,
this is not surprising because in normal human
brain, MDR1 is found mostly in the vicinity of blood
vessels, most probably on the endothelial cells. In
controls, nine of 10 showed MDR1 IR that is con-
sistent with the literature (Fig. 6). MRP1 staining
was detectable in capillary endothelium in 13
pathological tissues. It seems to be inconsistent
with the previous reports, which showed MRP1
staining in the choroid plexus epithelium only.
However, the demonstration of MRP1 IR on the
vascular endothelium may be related to MRP1
staining of astrocytic foot processes around the
capillaries as previously described. This finding
was confirmed by our control tissues, in which
we showed MRP1 IR in only one specimen.
No significant correlation between number of
AEDs, duration of epilepsy, seizure frequency
(before/after AEDs used) and MDR1/MRP1 expres-
sion on capillary endothelium was demonstrated
( p > 0.05).Table 3 Distribution of multidrug resistant proteins studie
FCD class Neurons Astrocytes Endothelial cells
MDR1 MRP1 MDR1 MRP1 MDR1 MRP1
IA (%)
 7.1 3.5 7.1 0 3.5 3.5
 0 3.5 3.5 3.5 3.5 7.1
+ 0 7.1 0 7.1 7.1 3.5
++ 7.1 0 3.5 3.5 0 0
IB (%)
 3.5 3.5 14.2 7.1 10.7 14.2
 3.5 3.5 0 3.5 0 3.5
+ 3.5 3.5 3.5 7.1 10.7 0
++ 7.1 7.1 0 0 0 0
IIA (%)
 25 0 25 7.1 21.4 17.8
 0 10.7 0 0 7.11 10.7
+ 3.5 28.5 7.1 32.1 7.1 10.7
++ 14.2 7.1 10.7 7.1 10.7 0
IIB (%)
 14.2 14.2 17.8 17.8 10.7 14.2
 0 0 0 0 0 0
+ 7.1 7.1 3.5 0 10.7 3.5
++ 0 0 0 0 0 3.5
Patient number 28 28 28 28 28 28
MDR1: multidrug resistance protein 1; MRP1: multidrug resistance-
moderate staining; (++): strong staining.
Histopathological classification14,15: IA: isolated architectural abnor
alities of malformations of cortical development); IB: architectur
neurons; IIA: Tylor-type focal cortical dysplasia (dysmorphic neurons
with dysmorphic neurons and balloon cells. The percentage of patiMDR1 and MRP1 expression in balloon cells
Balloon cells with prominent nucleoli have been
implicated in the epileptogenecity of FCD and the
origin of such cells with morphological changes is
still unclear. In this study, only six patients (21.4%)
revealed balloon cells and there were oneweak, one
strong MDR1 IR (Fig. 7a) and two moderate MRP1 IR
detected (Fig. 7b).
No significant correlation between number of
AEDs, duration of epilepsy, seizure frequency
(before/after AEDs used) and MDR1/MRP1 expres-
sion in balloon cells was demonstrated (p > 0.05).
Distribution of MDR1 and MRP1 according
to histopathological type
The statistical analysis demonstrated no statisti-
cally significant difference between the degree of
staining and the degree of histopathological type.
We were able to demonstrate the percentage of
each degree of staining with respect to the degree
of histopathological type (Table 3).d among the histopathological types
Giant neurons Dysmorphic neurons Balloon cells
MDR1 MRP1 MDR1 MRP1 MDR1 MRP1
0 0 - - - -
0 0 - - - -
0 0 - - - -
0 0 - - - -
21 10.5 - - - -
0 0 - - - -
0 5.2 - - - -
0 5.2 - - - -
42.1 36.8 42.1 21 - -
0 0 0 0 - -
0 5.2 0 31.5 - -
0 0 21 15.7 - -
21 21 26.3 5.2 66.6 66.6
5.2 0 0 10.5 16.6 0
0 10.5 0 15.7 0 33.3
5.2 0 5.2 0 16.6 0
19 19 19 19 6 6
associated protein 1; (): no staining; (): weak staining; (+):
malities (dyslamination, accompanied or not by other abnorm-
al abnormalities, plus giant or immature, but not dysmorphic
without or with balloon cells); IIB: architectural abnormalities
ents within each of staining indicated in parenthesis.
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Although the concept of drug transporters has been
originated from the researches in oncology, they
have been increasingly recognized and implicated
in the mechanism(s) of resistance to medical ther-
apy in refractory epilepsy. It is conceivable to think
that such drug transporters may play a role in
pharmacoresistance in epilepsy, analogous to drug
resistance in cancer. Tishler et al.17 were the first to
report that brain expression of MDR1 is markedly
increased in the majority of patients with medically
intractable partial (mostly temporal lobe) epilepsy
and suggested that MDR1 may play a clinically sig-
nificant role in refractoriness by decreasing the drug
concentration in the brain parenchyma. Later on
other groups of pathological lesions that often
associated with intractable epilepsy including,
FCD,6,7,12,13 TS,5 and DNETs6 have been studied.
FCD is a congenital maldevelopment of the cortex
of the brain and one of the most common malforma-
tions causing refractory epilepsy. There have been
only four reports, which demonstrated either
MDR1 or MRP1 or both in epileptogenic brain tissues
in limited number of patients with FCD
(Table 4).6,7,12,13 The pioneering study came from
Sisodiya et al.12 who studied four samples of surgi-
cally resected FCD and compared the findings with
normal necropsy brain tissue. They demonstrated
that giant dysplastic neurons showed cytoplasmic IR
for MRP1 in all four cases. Three of four samples also
had IR in reactive astrocytes in subcortical white
matter. However, the authors were not able to
demonstrate IR in balloon cells, glial components
of FCD. Neurons from adjacent to and distant from
the lesion did not show any IR. Furthermore,
neuronal and perivascular tissues showed no immu-
noreactions in four age-matched normal control.
This preliminary work raised the possibility that
over-expression of this drug transporters, also
502 H. Ak et al.known as brain protectors, may reduce the drug
concentration by exporting the drugs from the
CSF causing refractoriness in FCD.
The second study was also reported by the same
authors who extended their previous work12 by
increasing the number of the patients that included
DNET (eight patients), HS (eight patients), and FCD
(14patients).6 They studied IR forMDR1 in addition to
MRP1 in these patients and compared them with
histologically normal adjacent brain tissue. The find-
ings confirmed their previous work that in 14 cases
with FCD, both MDR1 and MRP1 expressions were
noted in reactiveastrocytes inall cases. IRwasalways
more frequent and intense in lesional reactive astro-
cytes than in reactive astrocytes belonging to the
adjacent normal tissue. Dysmorphic neurons in five
and balloon cells in two cases had MRP1 expression.
The adjacent normal cortex showed fewer IR for
MDR1 and MRP1 and no normal neurons were labeled
either with MDR1 or MRP1 antibody. Thus, they con-
sider that MDR1 and MRP1 in reactive astrocytes and
MRP1 in a fewdysmorphic neurons andballoon cells in
FCDmay represent the over-expression of drug trans-
porters that may lead to refractoriness in FCD.
The third study was performed by Aronica et al.7
who studied the expression of MDR1 and MRP1 in 15
patients with FCD containing abundant balloon
cells. They compared the lesional, perilesional,
and normal brain tissues and found that the normal
brain tissues expressed MRP1 below detection and
MDR1 was mainly found on the endothelial cells. The
vast majority of the patients with FCD (11 of 15)
showed strong IR for MDR1, as well as MRP1. Mod-
erate to strong MDR1 and MRP1 IR were observed in
large ballooned neuroglial cells. Perilesional regions
and normal brain tissues did not show IR for both
MDR1 and MRP1. The authors supported the hypoth-
esis that constitutive over-expression of MDRPs may
be the common mechanism underlying the pharma-
coresistance to AEDs in refractory epilepsy.
The last study was performed by Marchi et al.13
who confirmed that MDR1 was over-expressed in
blood vessels, astrocytes, and neurons in dys-
morphic regions extracted surgically from four
patients with FCD. They further demonstrated that
uptake of an AED, i.e. Phenytoin, was significantly
lower in astrocytes of an epileptic brain than normal
astrocytes, suggesting the limitation of the drug
uptake by MDR1.
The present study consisted of the largest series of
patients with FCD has confirmed the findings of pre-
vious four studieswhich showeda remarkableexpres-
sion of MDR1 and MRP1 in glial and neuronal tissue of
FCD when compared with normal brain. Further-
more, we supported to the findings demonstrated
in a rat model of temporal lobe epilepsy by Volk andLo¨scher18 that higher expression of MDRPs was not
secondary to high seizure frequency or duration of
epilepsy, and it is unlikely that treatment with AEDs
per se is responsible for the observed intralesional
over-expression of MDRPs, which may already be
present before the onset of seizure or exposure to
AEDs. Although it is known that normal brain does not
express MDR1 and MRP1 in neurons; over-expression
of MRP1 was mainly localized in neuronal component
of dysmorphic tissues. The neuronal expression of
MDR1andMRP1weredemonstrated ina largenumber
of specimens in our study included larger population
of patients with FCD than previously reported stu-
dies. Endothelial cells expressed principally MDR1 IR
and in agreementwith theprevious studies, endothe-
lial cells from the normal brain specimens demon-
strated MDR1 IR. Thus, our results also support the
current data that MDR1 are the vascular component
of cortical maldevelopment. MRP1 IR in dysmorphic
neurons was more abundant than MDR1. Neverthe-
less, findings including the present study support the
current notion that MDR1 and MRP1 as drug transpor-
ters are over-expressed in epileptogenic brain
regions, suggesting that they might lower local inter-
stitial drug concentrations and thereby reduce their
anti-epileptic effects, which may explain the refrac-
toriness to AEDs in FCD.
The multidrug resistant theory in medically
intractable epilepsy seems biologically plausible;
however, it remains to be proved. Although, the
experimental and clinical studies are still in their
infancy, they are encouraging and enable us to
explain at least one mechanism of drug resistance
in epilepsy. However, there is still debate related to
whether over-expression of drug transporters in epi-
leptogenic tissue is intrinsic (constitutive) or
induced/acquired as a consequence of epilepsy,
uncontrolled seizure, chronic use of AEDs, or combi-
nation of these factors. In animal models of temporal
epilepsy, a transient increase in drug transporter
concentrations in astroglia, neurons and brain capil-
lary endothelial cells following a seizure was demon-
strated which suggests the seizure themselves can
induce over-expression of drug transporters.19,20 On
the other hand, constitutive rather than inductive
over-expression of MDRPs has been demonstrated in
patients with intractable epilepsy secondary to cor-
tical maldevelopment and recently in a rat model of
temporal lobe epilepsy.18
Following the promising results drawn from the
studies described above, one may consider that
development of AEDs that bypass over-expressed
MDRPs could be a valuable approach for overcoming
drug resistance. For direct proof of principle, some
studies used MDR1 inhibitors and demonstrated that
addition of inhibitors greatly improved overall
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showed improved subjective quality of life.22 More-
over, current data indicate that at least seven major
AEDs including phenytoin, phenobarbital, carbama-
zepine, lamotrigine, gabapentin, felbamate, topir-
amate, are substrates for and transported by MDRPs
at the BBB.
Despite current promising data, possibility of
other mechanisms of drug resistance in epilepsy
cannot be disregarded; therefore the practical
use of MDRP inhibitors in the treatment of refractory
epilepsy definitely needs further studies to prove
the hypothesis.Conclusion
Based on the largest number of the patients with
FCD, we demonstrated that over-expression of the
best-known MDRPs; MDR1 and MRP1 are common
features of FCD. As a consequence, MDRPs may be a
target to design AED treatment regimen for over-
coming the drug intractability in epilepsy. However,
further studies will be required to clarify the roles of
drug transport proteins other than MDR1 and MRP1
for drug resistance in epilepsy.References
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